Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascendis Pharma A (ASND) Total Liabilities (2016 - 2025)

Ascendis Pharma A's Total Liabilities history spans 8 years, with the latest figure at $1.0 billion for Q4 2023.

  • For Q4 2023, Total Liabilities rose 23.95% year-over-year to $1.0 billion; the TTM value through Dec 2023 reached $1.0 billion, up 23.95%, while the annual FY2023 figure was $1.1 billion, 20.63% up from the prior year.
  • Total Liabilities for Q4 2023 was $1.0 billion at Ascendis Pharma A, up from $843.1 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $1.0 billion in Q4 2023 and bottomed at -$1000.0 million in Q4 2020.
  • The 5-year median for Total Liabilities is $230.3 million (2021), against an average of $241.3 million.
  • The largest annual shift saw Total Liabilities crashed 1234.7% in 2020 before it skyrocketed 266.15% in 2022.
  • A 5-year view of Total Liabilities shows it stood at $88.1 million in 2019, then plummeted by 1234.7% to -$1000.0 million in 2020, then soared by 123.03% to $230.3 million in 2021, then surged by 266.15% to $843.1 million in 2022, then rose by 23.95% to $1.0 billion in 2023.
  • Per Business Quant, the three most recent readings for ASND's Total Liabilities are $1.0 billion (Q4 2023), $843.1 million (Q4 2022), and $230.3 million (Q4 2021).